siRNAgen Therapeutics

In vivo experimental services are key preclinical analytical services that evaluate the efficacy, toxicity, and pharmacokinetic properties of test substances within a living organism. By administering test substances to various disease models and observing physiological responses, it is possible to directly confirm their actual effects in vivo.
The test substances are administered to experimental animals according to a defined protocol, and various parameters—such as changes in body weight, blood glucose levels, biomarkers in blood and tissues, survival rates, and behavioral changes—are analyzed to assess the drug’s mechanism of action and efficacy.
Furthermore, in vivo studies enable comprehensive analysis of interactions within the complex biological environment, making them highly effective for demonstrating real physiological responses that are difficult to confirm in cell-based experiments.
This service covers the entire standardized process, from disease model establishment → dosing design → sample collection and analysis → results reporting, and can be customized according to the client’s research objectives. A wide range of disease models, including diabetes, obesity, kidney diseases, cancer, and bone disorders, are available, allowing for precise and tailored preclinical study designs.
In vivo studies are offered in various service types depending on the study purpose, administration method, and model type. For detailed information, please refer to the "Order Information" page.

Overview

In vivo CRO and histopathological analysis services are key preclinical technologies that precisely evaluate the in vivo efficacy, safety, and mechanisms of action of drug candidates using disease animal models.
Leveraging its expertise in RNAi-based therapeutic development, siRNAgen Therapeutics provides customized study designs and quantitative, data-driven evaluation services for various indications, including inflammation, tumors, metabolic disorders, and kidney diseases.

Key Strengths

1. Customized In vivo Study Design Based on Specialized Disease Models

siRNAgen Therapeutics offers validated rodent disease models for a wide range of indications, including inflammation, tumors, metabolic disorders, and kidney diseases. We provide optimized, customized study designs and execution tailored to specific research objectives.

2. Expertise in RNAi Therapeutic Evaluation for Gene Targets

Leveraging specialized expertise in RNAi-based therapeutic development, we precisely conduct siRNA/SAMiRNA-induced gene expression knockdown studies and downstream biomarker analyses to enable functional target validation and accurate efficacy assessment.

3. Quantitative Efficacy and Toxicity Assessment Through Histopathology

Following the administration of test substances, major organs are collected for histopathological analyses such as H&E and IHC staining. This enables both quantitative and qualitative evaluation of drug efficacy and toxicity at the tissue level.

4. Wide Coverage of Disease Models and Evaluation Parameters

A broad range of disease models—such as diabetes (db/db), obesity, NAFLD, cancer (xenograft), pulmonary fibrosis, and depression—can be utilized, along with diverse evaluation parameters including body weight, blood glucose, and blood/tissue biomarkers, enabling support for a wide spectrum of research needs.

5. Fast and Transparent Reporting System

From sample analysis to report delivery, we provide rapid and accurate result reports (including IND-supporting documentation) through a standardized operational system and experienced professionals. Customized reports can also be provided upon client request.

6. Efficacy Evaluation Center

The Efficacy Evaluation Center is located in Munpyeong-dong, Daejeon, and spans approximately 330 m². It consists of four animal housing rooms, two necropsy rooms, and one pathology room. The facility can accommodate up to 1,500 rodents, all housed in individual cages to minimize cross-contamination and cross-infection, ensuring the highest research quality for our clients.